Radioactive pill tested in healthy men to map huntington Drug's path

NCT ID NCT07516899

Not yet recruiting Knowledge-focused Sponsor: Luye Pharma Group Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study will give 8 healthy men a single radioactive dose of LPM3770164, a drug being developed for Huntington disease. Researchers will measure how much of the drug is recovered in urine and stool, and identify its breakdown products. The goal is to understand how the drug is processed and eliminated, not to treat the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LPM3770164 (a radioactive drug)
What this could lead to: If successful, this study will show how the drug moves through and leaves the body, which is a necessary step before testing it as a treatment for Huntington disease.
What could go wrong: This is a very early, small study in just 8 healthy men, not people with Huntington disease. It is designed only to measure drug processing, not to treat or improve symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Huntington disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUNTINGTON DISEASE

Contacts and locations

Locations

Affiliated Hospital of Jiangnan University

Wuxi, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.